Jack Schuler Acquired 15000 shares of Accelerate Diagnostics, Inc. (AXDX) in an Insider Trading; Idt (IDT) Sentiment Is 0.91

March 7, 2018 - By Danny Collins

IDT Corporation, through its subsidiaries, operates primarily in the telecommunications and payment industries in the United States and internationally. The company has market cap of $295.11 million. It operates in two divisions, Telecom Platform Services and Consumer Phone Services. It currently has negative earnings. The Telecom Platform Services segment offers retail telecommunications, including international long-distance calling products; payment offerings, such as international and domestic airtime top-up, and international money transfer through its Boss Revolution platform; wholesale international long distance traffic termination; and hosted platform solutions comprising customized communications services that leverage its proprietary networks, platforms, and technology to cable companies and other service providers.

The well informed person Jack Schuler who is director of Accelerate Diagnostics Inc bought some 15,000 shares of the public company having a market value near $372,600 US Dollars which is based on a market stock price of $24.8 a share . In the last 30 days, he also purchased 55,000 shares that are worth approx $1.38 million USD. Obviously, the purchase attracted interest, as Mr. Jack presently holds 689,355 shares, accounting for 10%+ of the company’s total market capitalization. The insider transaction took place on March 06, 2018 and was unveiled inside a filing at the Washington-based Security and Exchange Commission’s website.

Investors sentiment decreased to 0.81 in Q3 2017. Its down 0.82, from 1.63 in 2017Q2. It dived, as 15 investors sold Accelerate Diagnostics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 38 raised stakes. 21.32 million shares or 11.33% more from 19.15 million shares in 2017Q2 were reported. Polar Llp reported 0.26% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Tower Cap Ltd Liability (Trc) holds 0% or 2,615 shares in its portfolio. Susquehanna Gp Llp has 149,833 shares for 0% of their portfolio. Barbara Oil invested in 0.14% or 9,000 shares. Bnp Paribas Arbitrage Sa has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Moreover, Plante Moran Financial Lc has 0.05% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 4,000 shares. Vanguard Group holds 1.29M shares. 18,789 are owned by Aqr Mgmt Ltd Llc. Metropolitan Life Insurance New York has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Royal State Bank Of Canada holds 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 5,311 shares. Quantbot Ltd Partnership has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). The New York-based Alliancebernstein Limited Partnership has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Strs Ohio stated it has 106,668 shares. Swiss Bank & Trust, a Switzerland-based fund reported 55,900 shares. Prelude Cap Limited Liability Company owns 6,321 shares for 0.01% of their portfolio.

The stock increased 0.39% or $0.1 during the last trading session, reaching $25.95. About 152,921 shares traded. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has risen 147.12% since March 7, 2017 and is uptrending. It has outperformed by 130.42% the S&P500.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.45 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Accelerate Diagnostics has $3400 highest and $17 lowest target. $30.33’s average target is 16.88% above currents $25.95 stock price. Accelerate Diagnostics had 9 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has “Overweight” rating given on Thursday, March 24 by JP Morgan. The rating was maintained by Piper Jaffray with “Buy” on Sunday, September 17. The firm has “Outperform” rating by William Blair given on Friday, January 8. JP Morgan maintained Accelerate Diagnostics, Inc. (NASDAQ:AXDX) rating on Tuesday, August 9. JP Morgan has “Overweight” rating and $25 target. The rating was initiated by Piper Jaffray with “Overweight” on Wednesday, December 16. The company was maintained on Thursday, August 3 by Piper Jaffray. BTIG Research upgraded the stock to “Neutral” rating in Tuesday, August 25 report. BTIG Research reinitiated the shares of AXDX in report on Wednesday, July 12 with “Buy” rating. The firm has “Neutral” rating by BTIG Research given on Wednesday, December 13.

Analysts await Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report earnings on May, 4. They expect $-0.33 EPS, down 22.22% or $0.06 from last year’s $-0.27 per share. After $-0.27 actual EPS reported by Accelerate Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.

Since October 12, 2017, it had 8 insider purchases, and 0 selling transactions for $10.14 million activity. 13,250 shares were bought by SCHULER JACK W, worth $268,843.

The stock decreased 1.74% or $0.21 during the last trading session, reaching $11.88. About 183,339 shares traded. IDT Corporation (IDT) has risen 41.75% since March 7, 2017 and is uptrending. It has outperformed by 25.05% the S&P500.

Since January 1, 0001, it had 1 buy, and 2 selling transactions for $79,583 activity.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: